https://www.selleckchem.com/pr....oducts/atezolizumab.
Hydrothermal duodenal mucosal resurfacing (DMR) is a safe, outpatient endoscopic procedure. REVITA-2, a double-blind, superiority randomised controlled trial, investigates safety and efficacy of DMR using the single catheter Revita system (Revita DMR (catheter and system)), on glycaemic control and liver fat content in type 2 diabetes (T2D). Eligible patients (haemoglobin A1c (HbA1c) 59-86 mmol/mol, body mass index≥24 and ≤40 kg/m , fasting insulin 48.6 pmol/L, ≥1 oral antidiabetic medication) enrolled in Europe and Brazil. Pri
Like
Comment
Share
